Topics
Sector
Geography
Subject

Videos Library

All Videos

1457
videos of thought-leading presentations and interactive panel discussions from life science industry visionaries and experts

The NextLevel LifeSciences Videos Library is the full collection of video recordings (and supporting documentation) from all NextLevel LifeSciences events.

Latest Videos

Presentation

The Patient as the Payer: What drives patients’ willingness-to-pay?

Related topics: Pharmaceutical/Biotech, Europe, Market Access & HEOR, Patient-Centricity & Care
Availability: FREE
Speaker

Adrien Gras
Vice President Europe, Market Access
GFK, UK

Presentation

Bio-similar, but different: Establishing (or defending) value through Multi-Criteria Decision Analytic (MCDA) modelling

Related topics: Pharmaceutical/Biotech, Europe, Market Access & HEOR, Biosimilars
Availability: FREE
  • How the complex characteristics of biologics (and biosimilars) contribute to perceived value to different stakeholders.
  • The salient issues facing Upstarts (marketers of biosimilars) and Defenders (marketers of “original” biologics) in communicating comparative worth to stakeholders.
  • How MCDA modelling methods can assist both groups in better defining and communicating value.
Speaker

Mason W. Russell
Vice President, Strategic Consulting (Life Sciences)
Truven, USA

Presentation

HTA in the changing development and regulatory landscape

Related topics: Pharmaceutical/Biotech, Europe, Market Access & HEOR
Availability: FREE
  • What is driving changes such as conditional market authorisation and adaptive pathways?
  • What are the challenges for HTA agencies and their evaluation approaches?
  • What are the critical success factors for pharma companies?
Speaker

Anke van Engen
Principal, Consulting Services
QuintilesIMS

Presentation

Building the market to gain market access in Asia-Pacific countries: From a transactional player to a strategic partner

Related topics: MedTech, Market Access & HEOR, Asia Pacific
Availability: FREE
  • What value does your technology bring to address the needs of the country’s health system?
  • How can you develop the market to create a receptive and favorable environment for your technology?
  • Case study: Established vs. emerging markets.
Speaker

Anne Smart
Director
Navigant, USA

Presentation

Gamification and mobile reinforcement: How science from Harvard Medical School is driving a new approach to healthcare training

Related topics: MedTech, Commercial, Global (non-specific), Digital & Technology
Availability: FREE
  • Ground breaking technology from Harvard Medical School.
  • Used by life science sales teams and healthcare professionals.
  • Extend retention of complex processes and facts from weeks to years.
  • Mobile and social gaming methods to drive adoption and motivation.
  • Maximise return on investment in product training.
     
Speaker

Louella Morton
VP International Sales & General Manager
Qstream

Presentation

Accelerating sales with sales driven marketing

Related topics: MedTech, Commercial
Availability: FREE

In today’s digital age, marketers can use marketing automation and analytics technology enabling them to be hyper-relevant to the customer via online channels. But what happens when the customer schedules a call or meeting with your sales team? How do you know whether or not your content performs well during this offline phase of the customer journey? Learn how to grow your business by supporting your sales and indirect channels with sales driven marketing.

Speaker

Pieterjan Bouten
Chief Executive Officer
Showpad, Belgium

Presentation

Roadmap to market access: Demonstrating value to purchasers

Related topics: MedTech, Market Access & HEOR, Commercial, Global (non-specific)
Availability: FREE
  • Analysis of the real case of a global medical device companythat launched an innovative device to prevent seriouscomplications of a disease and was facing significant market barriers across Europe.
  • In spite of the product’s clinical benefits, commercial teams couldnot quantify the value of the product to purchasers and decisionmakers.
  • The solution came with the development of a process positioningthe best product evidence to directly address the clinical andeconomic needs of stakeholders.
  • Commercial teams were able to quickly demonstrate and quantifyvalue, helping hospitals and clinics to understand the costs and benefits of adopting the medical innovation.
Speaker

Ernesto M. Nogueira 
Managing Director
ValueConnected, Netherlands

Presentation

Effectively incorporate communications in product commercialisation

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE
  • Developing and implementing a scientific strategy to effectively disseminate evidence and show value and engaging with diverse stakeholders.
  • Understanding how, when, and to whom you communicate evidence.
  • Benefits and challenges of consistent communications.
Speaker

Gillian Boucher
Director, Medical Writing and Editorial
Quintiles

Presentation

What do we call KOLs if we can’t call them “KOLs”?

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE
  • The term “KOL”: Too toxic for everyday use, or still the best tool for the job?
  • Results from a survey of pharma and KOLs on the use of terminology alternatives.
  • Should pharma work towards using one universal replacement for the term “KOL”?
  • How does this change the way we engage with KOLs and stakeholders in medical affairs?
  • And what exactly do KOLs think of all this?
Speaker

Sanjay Singhvi  
​Director
System Analytic, UK

Presentation

Quality not quantity in observational research: Delivering the right studies at the right time in the right way to meet your real world evidence needs

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE
  • Defining quality in the context of today’s observational research needs.
  • Developing a framework to deliver quality every time you conduct non-interventional studies.
Speaker

Louise Parmenter 
Global Head of Operations, Epidemiology & Outcomes Research
Real-World & Late Phase Research
Quintiles

Presentation

MSL Technology Showcase

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific), Digital & Technology, Medical Science Liaison
Availability: FREE
Speaker

Gijs Hubben
CEO
BaseCase, Germany

Presentation

Flexible resourcing & talent management models for medical affairs teams

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE
  • Evaluating and developing a medical affairs team’s skill sets for more flexibility.
  • Developing a life-cycle dependent model for flexible medical affairs resourcing.
  • The impact of a flexible resourcing approach on talent acquisition.
  • The role of strategic outsourcing for medical affairs.
Speaker

Keith Morris
Vice President, Medical Affairs
Campbell Alliance, USA

Presentation

Multilateral recruitment approach for early phase oncology trials: Weights and balances

Related topics: Pharmaceutical/Biotech, Clinical, Global (non-specific), Oncology
Availability: FREE
  • Key challenges in early phase oncology recruitment.
  • Therapeutic, supportive and other compounds from trial management perspective.
  • Pros and cons of early phase trials for the investigator and for the cancer patient.
  • Role and potential of professional CPU (Clinical Pharmacology Unit) within indication.
  • Satellite Centre Concept for proper recruitment and controlled quality.
Speaker

Istvan Udvaros 
Medical Director, Project Director of Oncology
SGS LSS Clinical Research, Belgium

Presentation

Mass balance/ADME studies in oncology patients: Successful answers to the challenge in Central and Eastern Europe

Related topics: Pharmaceutical/Biotech, Europe, Clinical, Central Eastern Europe, Oncology
Availability: FREE
  • Patient pharmacology services: Concept and operational set up.
  • ADME concepts, incl. micro-dose and tracer-dose.
  • Underlying dossier requirements incl. preclinical safety package.
  • General design considerations incl. radiodose and radioburden calculation.
  • Devil is in the details: Operational challenges.
  • Selection of geographic region and patient population.
  • Ethical aspects.
Speaker

Agnes Rethy 
Associate Director of Clinical Operations
EDS Patient Pharmacology Services
PRA Health Services

Presentation

A matter of perspective: Evolving the MSL role for the long-term development of next-generation KOLs

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific), Medical Science Liaison
Availability: FREE
  • What is the role of an MSL today in developing strategic relationships with KOLs.
  • Learn what a typical ‘day in the life’ of an MSL is like.
  • Is the role of an MSL here to stay for the long term?
Speaker

Sital Kotecha
Medical Strategy Director, Europe
Veeva Systems, UK

Presentation

Pre-Market Communications: Reaching your audience in today’s complex environment

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE
  • The importance and benefits of an effective pre-market communication plan.
  • The when, where and how of the various elements who need to be engaged.
  • Development and implementation of the plan: Where the magic happens and results are driven!
  • The essential elements to any pre-market communication plan.
  • The need for achieving balance between the speed, timing and volume of pre-market communications.
Speaker

Tim Day
CEO & Principal
Innovative Strategic Communications, USA

Presentation

RWE: The good, the bad and the necessary

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE
  • A review of success rates in recent drug launches.
  • Look at where launches haven’t gone well and where RWE could have played a role in mitigating this: The bad.
  • Building an Integrated Medical Plan to prepare for success (Begin with the end in mind): The good.
  • The resource vs. demand challenge and the consequent benefit of outsourcing: The necessary.
Speaker

Alistair MacDonald
Executive Director, Real World Strategy
INC Research, UK

Presentation

Integrating real-world evidence into global market access planning

Related topics: Pharmaceutical/Biotech, Market Access & HEOR, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE
  • Regulators and payer considerations of the ‘key value drivers’ in RWE generation.
  • Highly successful RWE strategies, study designs and best practices and how they differ across global markets.
  • How medical affairs can best utilise RWE to support market access decision making.
Speakers

Leanne Larson
Vice President and Global Head, Observational Research
Parexel, USA

Oliver Leatham
Vice President and Head, Pricing and Market Access
Parexel, UK

Presentation

Applying the patient perspective to medical planning

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific), Patient-Centricity & Care
Availability: FREE
  • Apply a single framework for patient centricity in medical affairs.
  • Uncover what patients value and how it changes on their treatment journey.
  • Structure and prioritise innovative medical activities in a patientcentric way.
Speaker

Dominic Sloane 
Development Director
Adelphi Communications, United Kingdom

Presentation

Getting to world class medical affairs

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific), Digital & Technology
Availability: FREE
  • Challenges facing medical affairs functions today.
  • Medical affairs transformation as pipelines shift to specialty care.
  • Getting to ‘world class’ through focus on delivering an exceptional stakeholder experience.
Speaker

Sital Kotecha 
Medical Strategy Director, Europe
Veeva Systems, UK

Presentation

Success case study: Driving bottom-line surge using salesforce analytics, salesforce sizing and deployment issues

Related topics: MedTech, Commercial, Global (non-specific)
Availability: FREE
  •  Promotion response modelling for ROI on sales calls to derive optimal size.
  •  Territory alignment based on Potential Index and Workload Index.
  •  Incentive design for salesforce based on fairness, motivation and financial risk.
Speaker

Sumit Mehta
Managing Director
Cetas Healthcare Insights

Presentation

Improving commercial effectiveness at scale: A Boston Scientific case study

Related topics: MedTech, Commercial, Global (non-specific)
Availability: FREE
  •  Identifying commercial learning challenges.
  •  Shifting middle performers.
  •  Implementing solutions to support continuous commercial learning at scale.
  •  The path to continued commercial effectiveness.
Speakers

Jay Bratcher 
Training Manager, New Cardio, Europe 
Boston Scientific, UK

Michael Quann
Director Strategic Account
Qstream, Ireland

Presentation

How reimbursement/funding drive sales and adoption for medical technologies?

Related topics: MedTech, Market Access & HEOR, Commercial, Global (non-specific)
Availability: FREE
  • Overview of the main reimbursement systems in Europe.
  • Price: The main barrier for medical technology.
  • When is it (really) necessary to apply for reimbursement?
  • Demonstrating value to access healthcare payment pathways.
  • Moving ahead: The new EU perspective on medical innovations.
Speaker

Ernesto Nogueira
Managing Director 
ValueConnected

Presentation

CPQ and Tender Management: How can I optimise my commercial strategy?

Related topics: MedTech, Market Access & HEOR, Commercial, Global (non-specific)
Availability: FREE

Prioritising and targeting the best business opportunities is crucial for medical device
companies to create an optimal offering strategy while controlling and minimising
discounting. Therefore it is critical for global pricing, commercial and marketing
leaders to standardise their price configuration, quotes and tender processes with
best practices. This approach will lead to new business and optimal deal structures,
resulting in higher revenues and margins.

Speaker

James Robinson
Director Industry Solutions
ModelN, Switzerland

Presentation

The importance of achieving recruitment targets in MENA

Related topics: Pharmaceutical/Biotech, Clinical, Middle East
Availability: FREE
  •  Why is recruitment important?
  •  Issues seen in studies (generally not just MENA).
  •  What are the possible reasons for this?
  •  Are there differences between MENA and ROW in patient recruitment numbers and retention rates?
  •  How could we actively prevent these issues?
  •  Case studies (both good and bad) & lessons learned.
Speaker

Myriam El-Khazen
General Manager 
INC Research, Greece

Presentation

Mapping real-world centers: Can it be done?

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Asia Pacific
Availability: FREE
Speaker

Karen Wai
Vice President, Regional Managing Director Real-World & Late Phase Research, Asia Pacific
Quintiles, Singapore

Presentation

RWE in Asia: Has its time finally come?

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Asia Pacific
Availability: FREE
  •  Current state of RWE in Asia markets.
  •  Key trends and how it is evolving.
  •  What this means for healthcare companies.
Speaker

Sheryl Jacobson
Asia Head of Life Science and Healthcare Consulting 
Deloitte

Presentation

Opportunities and challenges using unsolicited, self-reported, health outcomes data from open web-based media sources

Related topics: Pharmaceutical/Biotech, IT & Big Data, Global (non-specific), Digital & Technology
Availability: FREE
  • An ever-increasing number of individuals routinely contribute and consume solicited and unsolicited information about a variety of health-related issues using a wide range of internet and social media channels.
  • Personal web-based reports on health status, symptoms, treatments and associated interventions may provide a rich source of data to support discovery, clinical development and post marketing analytics.
  • A key challenge in the applicability and utility of these data is related to the veracity, accuracy and reliability of information collected from web-based media sources.
Speaker

Mark Wolff
Advisory Industry Consultant, Chief Health Analytics Strategist
Health & Life Sciences Global Practice, SAS Institute, USA

Presentation

Leading patient engagements: From patient data analytics to mHealth interventions

Related topics: Pharmaceutical/Biotech, IT & Big Data, Global (non-specific), Patient-Centricity & Care, Digital & Technology
Availability: FREE
Speaker

Alexander Frenzel
Senior Manager, Business Development T&A, QuintilesIMS, Germany

Presentation

Bridging the gap between good science and clinical application

Related topics: Pharmaceutical/Biotech, Clinical, IT & Big Data, Discovery & R&D Innovation, Global (non-specific)
Availability: FREE
Speaker

Jonathan Sheldon
Global Vice President, Healthcare | Health Sciences
Global Business Unit, Oracle Health Sciences, UK

Presentation

Optimising clinical trial design and execution using Real-World Data and Predictive Analytics

Related topics: Pharmaceutical/Biotech, Real-World Evidence & Late-Phase Research, Clinical, IT & Big Data, Global (non-specific)
Availability: FREE
Speaker

John Rigg
Head of Predictive Analytics Real-World Insights, QuintilesIMS, UK

Presentation

Demystifying Artificial Intelligence for Pharma in the Era of Big Data

Related topics: Pharmaceutical/Biotech, IT & Big Data, Discovery & R&D Innovation, Global (non-specific)
Availability: FREE
  • Convergence of data, technology and advances in the field ofneural networks.
  • Increased opportunities for the use of real-world evidence data sets from the genome revolution, clinical trials, medical imaging and electronic health records.
  • Accelerate the use of Artificial Intelligence (AI) within Pharma R&D to develop actionable insights.
Speaker

Andrea de Souza
Global Business Development Lead, NVIDIA, USA

Presentation

How deep data and predictive analytics can enhance R&D portfolio management

Related topics: Pharmaceutical/Biotech, Clinical, IT & Big Data, Discovery & R&D Innovation, Global (non-specific)
Availability: FREE
  • Identify new patient target groups for innovative drug development by applying predictive analytics to real world and trial data.
  • Enhance R&D productivity by mapping the real world using predictive analytics.
  • Facilitate the implementation of Adaptive Pathways through predictive analytics.
Speakers

Kerstin Bode-Greuel
Dir. Business Development & Marketing RWE
QuintilesIMS, Germany

Rolf Günther
Chief Information Officer
Qlaym Healthcare, Germany

Presentation

HTA, funding & reimbursement of cell & gene therapies: A global perspective

Related topics: Pharmaceutical/Biotech, Market Access & HEOR, Global (non-specific)
Availability: FREE
  • Health technology assessment challenges in assessing clinical and cost effectiveness of cell / gene therapies.
  • Who pays? Healthcare system determinants of funding/reimbursement paradigm.
  • Affordability: Pricing and budget impact challenges
Speaker

W. Neil Palmer
President & Principal Consultant
PDCI Market Access Inc.

Presentation

Central and Eastern Europe: Diversity to tame, market access potential to unveil

Related topics: Pharmaceutical/Biotech, MedTech, Europe, Market Access & HEOR, Central Eastern Europe
Availability: FREE
  • Regional diversities in approaches to public funding decision making.
  • Comparative measures to enable informed allocation of company strategic efforts.
  • Analysis of public funding decision making practice as a tool to identify risks and opportunities and to provide unbeatable arguments to CEE decision makers
Speaker

Norbert Wilk
Director, Market Access Consulting
Arcana Institute, Poland

Presentation

Devising value-enhancing strategies for biosimilars: A conceptual framework

Related topics: Pharmaceutical/Biotech, Market Access & HEOR, Biosimilars
Availability: FREE
  • Is differentiation possible or even necessary in the biosimilars market? Although the impetus for a biosimilar development originally might have been solely economic, we argue thatmmanufacturers should devise a value proposition for biosimilars that moves beyond price, demonstrating value to payers, physicians, and patients.
  • Presenting a unifying value framework as a guiding tool for biosimilar manufacturers supporting internal processes - for example: Building internal business cases for differentiating concepts with the end goal to develop a value-enhancing strategy.
Speaker

Sotiris Rompas
Director
Boston Healthcare, USA

Presentation

Biologics, biosimilars, and interchangeable biologics: US update after first launch

Related topics: Pharmaceutical/Biotech, USA, Market Access & HEOR, Biosimilars
Availability: FREE
  • The US is essentially a “secondary” market for biosimilars; as such, what can be learned from other markets?
  • The business model for biosimilars, neither branded or generic products, is likely to be different in the US than in other markets, especially when it comes to pricing. How will business models be structured and operate?
  • With only 5 applications and 1 approval to date, there isn’t yet a clear regulatory pathway for biosimilars in the US. What might that pathway look like when more fully developed?
  • With originators of branded products making more defensive manoeuvres in the US than in other countries, lifecycle management of biosimilars is likely to be different in the US than elsewhere. What differences will there be?
Speaker

Kathleen E. Hughes
Vice President, Avalere Health, USA

Presentation

Blueprint for market access: Strategic insights from the regulatory and HTA review process

Related topics: Pharmaceutical/Biotech, Europe, Market Access & HEOR
Availability: FREE

An interactive session exploring the lifecycle of a drug including:

  • Comparison of regulatory and HTA agency clinical trial evaluations
  • Impact of the label indications on the HTA review process
  • HTA opinion on submitted evidence
Speaker

Yin Ho
CEO
Context Matters Inc., USA

Presentation

Leveraging Real-World Evidence (RWE) in medical device reimbursement

Related topics: MedTech, Europe, Market Access & HEOR, Real-World Evidence & Late-Phase Research
Availability: FREE
  • What do we mean by RWE?
  • Usefulness and limitations of RWE in supporting medical device reimbursement.
  • Case studies of the successful use of RWE in device reimbursement.
  • Summary.
Speaker

Stuart Mealing
Principal Economist, European Practice Lead
ICON, UK

Presentation

Building economic evidence towards compelling value propositions

Related topics: MedTech, Europe, Market Access & HEOR
Availability: FREE
  • Early stage or commercialisation: When is the right moment to focus on economic evidence?
  • Identifying what decision-makers are looking for.
  • Less is more: Identifying the relevant data to support value claims.
  • Case example: From evidence to compelling value proposition.
Speaker

Ernesto M. Nogueira
Managing Director
ValueConnected, Netherlands

Presentation

Demonstrating value in the changing US healthcare landscape

Related topics: MedTech, USA, Market Access & HEOR
Availability: FREE
  • The changing US landscape.
  • Evolving care delivery and incentive models.
  • Implications for innovators.
  • Organising to demonstrate value in the new environment
Speaker

Robert Wenthold
Executive Director
Boston Healthcare Associates

Presentation

NICE’s Medical Technologies Evaluation Programme: A global view of a national HTA

Related topics: MedTech, Europe, UK, Market Access & HEOR
Availability: FREE
  • How applicable is MTEP outside of England?
  • How does MTEP compare to other MedTech HTA?
  • What benefit is there to submitting to MTEP?
Speaker

Joanna Entwistle
Principal Consultant, GFK Market Access, UK

Presentation

Enhancing your medical affairs communications practices

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE

How do we avoid the greatest threat to carefully crafted medical strategy – the inevitable boiling down of delicately nuanced arguments into bullet points, charts and tables? To the outside observer it appears to be largely generic and is hardly reassuring to senior stakeholders who must bless it, or clear to those who must ultimately implement it. This presentation will discuss how to create and communicate your medical strategy in a way that informs and inspires the reader.

Speaker

Robert Barker
CEO, Succinct Medical Communications, UK

Presentation

Digital medical communications: HCP demand and industry supply

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific), Digital & Technology
Availability: FREE
  • 2015 research highlights: HCP demand versus industry supply of medical content.
  • Types, sources, formats and funding of medical content: HCP behaviour and preferences.
  • Closing the gap: Overcoming challenges to meeting audience needs and increasing engagement.
  • Independent platforms: Why and how to work with them for targeted audience reach.
Speaker

Tiberio Catania
Commercial Director
EPG Health Media, UK

Presentation

Assessing the value of quantitative metrics to help identify & engage KOLs

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE
  • Findings from an analysis of nearly a million data points comprising 1000 KOLs across 12 therapy areas.
  • Which quantitative metrics/characteristics correlate most closely with “KOL status”?
  • Disparity between qualitative & quantitative metrics: Does Qual add anything beyond the Quant?
  • What about identifying specific KOL subgroups? e.g. Digital KOLs,Rising stars & Orphan diseases.
  • How to apply this research to create in-house protocols for firstpass identification and validation of KOLs, easily and quickly?
Speaker

Sanjay Singhvi
Director, System Analytic, UK

 

Presentation

Disrupting conventions in medical affairs communications

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE
  • Address key medical affairs communication challenges: Case study review.
  • Disrupt traditional conventions to optimise medical strategy, hit communication objectives and maximise ROI.
  • Integrate digital technologies to gain better insight, foster more valued engagement and vitalise healthcare professional education.
  • Empower your teams to drive effective, consistent and compelling external communications.
Speakers

Chris Gray
President & Managing Director, Adelphi Communications, UK

Anne Marriott
Deputy Managing Director,
Adelphi Communications, UK

Presentation

50 Shades of real world evidence

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE
  • Dynamic mosaic of stakeholders, strategic drivers and key challenges.
  • ‘Late becomes Early’: Changing time frame of late-phase research.
  • The concept of best practices as a ‘Net Force’.
Speaker

Filip Rozewski
International Business Development
MediNeos Observational Research, Poland

Presentation

Late-phase & PASS study design considerations: Case study

Related topics: Pharmaceutical/Biotech, Europe, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Regulations & Ethics
Availability: FREE
  • When would you choose a retrospective design over a prospective design when planning for a PASS as part of a postmarketing commitment?
  • What have we seen in the PRAC feedback in the past year?
Speaker

Bettina Rillmann
Associate Director, Scientific Affairs
PRA Health Sciences, Germany

Presentation

From identification of gaps to sound prospective research: A strategic approach to medical affairs

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE
  • Using existing information and prospective research in evidence generation.
  • Strategic planning and tactical decision making in RWE datageneration and utilisation.
Speaker

Xavier Fournie
Corporate Medical Director, Executive Vice-President, Global Medical Affairs – Real World Evidence, MAPI, France

Presentation

Best practice approaches in phase 4 clinical operations and implementation

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE
Speaker

Alexandra Adams
Director, Late Phase, Europe
Chiltern, UK

Register to view both free videos and browse premium content (and event documentation).

1457
videos of thought-leading presentations and interactive panel discussions from life science industry visionaries and experts
300+
new videos added every year!